Literature DB >> 17724324

Human papillomavirus vaccines launch a new era in cervical cancer prevention.

Meenakshi Dawar1, Shelley Deeks, Simon Dobson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17724324      PMCID： PMC1950188          DOI： 10.1503/cmaj.070771

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  32 in total

1.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

Authors:  Luisa L Villa; Kevin A Ault; Anna R Giuliano; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Darron R Brown; Alex Ferenczy; Diane M Harper; Laura A Koutsky; Robert J Kurman; Matti Lehtinen; Christian Malm; Sven-Eric Olsson; Brigitte M Ronnett; Finn Egil Skjeldestad; Margareta Steinwall; Mark H Stoler; Cosette M Wheeler; Frank J Taddeo; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Rocio Marchese; Mark T Esser; Janine Bryan; Kathrin U Jansen; Heather L Sings; Gretchen M Tamms; Alfred J Saah; Eliav Barr
Journal:  Vaccine       Date:  2006-05-15       Impact factor: 3.641

2.  Meta-analysis of Pap test accuracy.

Authors:  M T Fahey; L Irwig; P Macaskill
Journal:  Am J Epidemiol       Date:  1995-04-01       Impact factor: 4.897

Review 3.  Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease.

Authors:  Charles J N Lacey; Catherine M Lowndes; Keerti V Shah
Journal:  Vaccine       Date:  2006-08-31       Impact factor: 3.641

4.  Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy.

Authors:  M Lehtinen; I Idänpään-Heikkilä; T Lunnas; J Palmroth; E Barr; R Cacciatore; R Isaksson; M Kekki; P Koskela; E Kosunen; M Kuortti; L Lahti; T Liljamo; T Luostarinen; D Apter; E Pukkala; J Paavonen
Journal:  Int J STD AIDS       Date:  2006-04       Impact factor: 1.359

5.  Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Authors:  Stan L Block; Terry Nolan; Carlos Sattler; Eliav Barr; Katherine E D Giacoletti; Colin D Marchant; Xavier Castellsagué; Steven A Rusche; Suzanne Lukac; Janine T Bryan; Paul F Cavanaugh; Keith S Reisinger
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

6.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

7.  Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

Authors:  Keith S Reisinger; Stan L Block; Eduardo Lazcano-Ponce; Rudiwilai Samakoses; Mark T Esser; Joanne Erick; Derek Puchalski; Katherine E D Giacoletti; Heather L Sings; Suzanne Lukac; Frances B Alvarez; Eliav Barr
Journal:  Pediatr Infect Dis J       Date:  2007-03       Impact factor: 2.129

8.  Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.

Authors:  Kevin A Ault
Journal:  Lancet       Date:  2007-06-02       Impact factor: 79.321

9.  Sociodemographic factors associated with high-risk human papillomavirus infection.

Authors:  Jessica A Kahn; Dongmei Lan; Robert S Kahn
Journal:  Obstet Gynecol       Date:  2007-07       Impact factor: 7.661

10.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.

Authors:  L L Villa; R L R Costa; C A Petta; R P Andrade; J Paavonen; O-E Iversen; S-E Olsson; J Høye; M Steinwall; G Riis-Johannessen; A Andersson-Ellstrom; K Elfgren; G von Krogh; M Lehtinen; C Malm; G M Tamms; K Giacoletti; L Lupinacci; R Railkar; F J Taddeo; J Bryan; M T Esser; H L Sings; A J Saah; E Barr
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640
View more
  8 in total

1.  Conserved region 3 of human papillomavirus 16 E7 contributes to deregulation of the retinoblastoma tumor suppressor.

Authors:  Biljana Todorovic; Katherine Hung; Paola Massimi; Nikita Avvakumov; Frederick A Dick; Gary S Shaw; Lawrence Banks; Joe S Mymryk
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

2.  Systematic analysis of the amino acid residues of human papillomavirus type 16 E7 conserved region 3 involved in dimerization and transformation.

Authors:  Biljana Todorovic; Paola Massimi; Katherine Hung; Gary S Shaw; Lawrence Banks; Joe S Mymryk
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

3.  An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.

Authors:  Khairunadwa Jemon; Vivienne Young; Michelle Wilson; Sara McKee; Vernon Ward; Margaret Baird; Sarah Young; Merilyn Hibma
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

4.  A Protocol for the secure linking of registries for HPV surveillance.

Authors:  Khaled El Emam; Saeed Samet; Jun Hu; Liam Peyton; Craig Earle; Gayatri C Jayaraman; Tom Wong; Murat Kantarcioglu; Fida Dankar; Aleksander Essex
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

Review 5.  Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines.

Authors:  Anna Lucia Tornesello; Maria Tagliamonte; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

Review 6.  Involvement of Human Papillomaviruses in Cervical Cancer.

Authors:  Xuelian Wang; Xiumin Huang; Youzhong Zhang
Journal:  Front Microbiol       Date:  2018-11-28       Impact factor: 5.640

Review 7.  Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.

Authors:  Stefania Cuzzubbo; Sara Mangsbo; Divya Nagarajan; Kinana Habra; Alan Graham Pockley; Stephanie E B McArdle
Journal:  Front Immunol       Date:  2021-02-17       Impact factor: 7.561

8.  HPV Vaccine Beliefs and Correlates of Uptake Among Hispanic Women and Their Children on the US-Mexico Border.

Authors:  Jessica Calderón-Mora; Tamanna Ferdous; Navkiran Shokar
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.